

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VON DER KAMMER *et al.*

Appl. No.: *To Be Assigned (U.S. National
Phase of PCT/EP2005/050850; Int'l. Filing
Date: February 28, 2005)*

Filed: *Herewith*

For: **Diagnostic and Therapeutic Use of
MAL2 Gene and Protein for
Neurodegenerative Diseases**

Confirmation No.: *To Be Assigned*

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 2335.0190000/SRL/PAC

Preliminary Amendment and Submission of Sequence Listing

Mail Stop PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Sequence Listing begin on page 4 of this paper and include an attached sequence listing.

Amendments to the Claims are reflected in the listing of claims which begin on page 5 of this paper.

Remarks begin on page 13 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net

addition of claims) are hereby authorized to be charged to our Deposit Account No.

19-0036.